KYMR

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (KYMR) has 19 SEC Form 4 filings (190 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jul 8, 2026.

The most active filer is Director Booth Bruce with 11 filings. Insiders have net sold $396.1M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Nello Mainolfi
  • Employees:208
  • HQ:Watertown, MA, US
  • IPO:2020-08-21

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$417.8M

reported sales (SEC code S)

Unique Insiders

7

in the rolling window

Market Cap

$9.4B

latest known value

Source
Sale$6.0MJul 8SEC ↗
Jacobs Bruce N.First filing
Sale$8.9MJul 2SEC ↗
Sale$387KJul 2SEC ↗
Mainolfi NelloFirst filing
Sale$9.2MJul 2SEC ↗
Sale$16.6MJul 2SEC ↗
Sale$51.6MJun 30SEC ↗
Sale$173.7MJun 26SEC ↗
Sale$65.1MJun 26SEC ↗
Sale$141KJun 26SEC ↗
Sale$13.5MJun 26SEC ↗
Sale$570KJun 25SEC ↗
Sale$27.6MJun 23SEC ↗
Booth BruceFirst in 6 months
Sale$10.6MJun 23SEC ↗
Booth BruceFirst in 6 months
Sale$10.5MJun 23SEC ↗
Goodman NoahFirst filing
Sale$248KJun 22SEC ↗
Chadwick Jeremy GFirst filing
Sale$1.0MMay 27SEC ↗
Chadwick Jeremy GFirst filing
Sale$349KMay 27SEC ↗
Ridloff ElenaFirst filing
Sale$261KMay 11SEC ↗
Sale$21.1MDec 12SEC ↗
Sale$557KDec 12SEC ↗
Sale$62KDec 12SEC ↗

Related companies

Kymera Therapeutics, Inc. is in the Healthcare sector.